Factor XIIIA and clot strength after cardiopulmonary bypass

被引:66
作者
Chandler, WL
Patel, MA
Gravelle, L
Soltow, LO
Lewis, K
Bishop, PD
Spiess, BD
机构
[1] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Surg, Seattle, WA 98195 USA
[3] Zymogenet Inc, Seattle, WA 98105 USA
[4] Med Coll Virginia, Dept Anesthesiol, Richmond, VA USA
[5] SE Anesthesia Associates, Dallas, TX USA
关键词
factor XIII; clot strength; cardiopulmonary bypass; thromboelastograph;
D O I
10.1097/00001721-200103000-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reduced factor XIIIA levels and decreased clot strength have been associated with increased bleeding after cardiopulmonary bypass (CPB). The purpose of this study was to evaluate the relationship between hemostatic factors, including factor XIIIA, and clot strength before, during and after CPB. Factor XIIIA antigen, platelet counts, fibrinogen, factor V activity, tissue plasminogen activator and clot strength (by thromboelastograph) were measured at baseline, after 45 min of CPB, at the end of CPB and 4 h post-operatively in 34 patients. Baseline factor XIIIA antigen was 5.2 +/- 1.4 mg/l. On average, factor XIIIA levels dropped to 64% and clot strength to 77% of baseline values after 45 min on CPB and remained below baseline during the immediate post-operative period. Clot strength was significantly correlated (r = 0.81) with platelet count and fibrinogen but not plasma factor XIIIA levels. Addition of 10 mg/l recombinant factor XIII{a(2)} significantly increased clot strength. Postoperative bleeding at 2 h was inversely correlated with platelet count, factor XIIIA antigen and dot strength measured at the end of CPB. Maintenance of adequate platelet counts and factor XIIIA levels at the end of CPB may play a role in maintaining clot strength and reducing blood loss. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 18 条
[1]  
AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402
[2]  
BABSON AL, 1975, AM J CLIN PATHOL, V64, P817
[3]   EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF HUMAN FACTOR-XIII IN SACCHAROMYCES-CEREVISIAE [J].
BISHOP, PD ;
TELLER, DC ;
SMITH, RA ;
LASSER, GW ;
GILBERT, T ;
SEALE, RL .
BIOCHEMISTRY, 1990, 29 (07) :1861-1869
[4]   PROTHROMBIN TIMES AND CLOTTABLE FIBRINOGEN DETERMINATION ON AN AUTOMATED COAGULATION LABORATORY (ACL-810) [J].
CASTILLO, JB ;
FARAG, AM ;
MAMMEN, EF ;
SACHS, RJ .
THROMBOSIS RESEARCH, 1989, 55 (02) :213-219
[5]  
Chandler WL, 1995, SEMIN THROMB HEMOST, V21, P1
[6]  
CHANDLER WL, 1989, J LAB CLIN MED, V113, P362
[7]  
Despotis G J, 1999, Semin Thorac Cardiovasc Surg, V11, P84
[8]   The effect of Factor XIII on bleeding in coronary surgery [J].
Gödje, O ;
Haushofer, M ;
Lamm, P ;
Reichart, B .
THORACIC AND CARDIOVASCULAR SURGEON, 1998, 46 (05) :263-267
[9]   ECONOMIC-IMPACT OF INAPPROPRIATE BLOOD-TRANSFUSIONS IN CORONARY-ARTERY BYPASS GRAFT-SURGERY [J].
GOODNOUGH, LT ;
SOEGIARSO, RW ;
BIRKMEYER, JD ;
WELCH, HG .
AMERICAN JOURNAL OF MEDICINE, 1993, 94 (05) :509-514
[10]  
Gootenberg J E, 1998, Curr Opin Hematol, V5, P372, DOI 10.1097/00062752-199811000-00003